title: Systematic review of influenza resistance to the neuraminidase inhibitors.
abstract: BACKGROUND
  Antivirals play a critical role in the prevention and the management of influenza. One class of antivirals, neuraminidase inhibitors (NAIs), is effective against all human influenza viruses. Currently there are two NAI drugs which are licensed worldwide: oseltamivir (Tamiflu®) and zanamivir (Relenza®); and two drugs which have received recent approval in Japan: peramivir and laninamivir. Until recently, the prevalence of antiviral resistance has been relatively low. However, almost all seasonal H1N1 strains that circulated in 2008-09 were resistant to oseltamivir whereas about 1% of tested 2009 pandemic H1N1 viruses were found to be resistant to oseltamivir. To date, no studies have demonstrated widespread resistance to zanamivir. It seems likely that the literature on antiviral resistance associated with oseltamivir as well as zanamivir is now sufficiently comprehensive to warrant a systematic review.The primary objectives were to systematically review the literature to determine the incidence of resistance to oseltamivir, zanamivir, and peramivir in different population groups as well as assess the clinical consequences of antiviral resistance.
  
  
  METHODS
  We searched MEDLINE and EMBASE without language restrictions in September 2010 to identify studies reporting incidence of resistance to oseltamivir, zanamivir, and peramivir. We used forest plots and meta-analysis of incidence of antiviral resistance associated with the three NAIs. Subgroup analyses were done across a number of population groups. Meta-analysis was also performed to evaluate associations between antiviral resistance and clinical complications and symptoms.
  
  
  RESULTS
  We identified 19 studies reporting incidence of antiviral resistance. Meta-analysis of 15 studies yielded a pooled incidence rate for oseltamivir resistance of 2.6% (95%CI 0.7% to 5.5%). The incidence rate for all zanamivir resistance studies was 0%. Only one study measured incidence of antiviral resistance among subjects given peramivir and was reported to be 0%. Subgroup analyses detected higher incidence rates among influenza A patients, especially for H1N1 subtype influenza. Considerable heterogeneity between studies precluded definite inferences about subgroup results for immunocompromised patients, in-patients, and children. A meta-analysis of 4 studies reporting association between oseltamivir-resistance and pneumonia yielded a statistically significant risk ratio of 4.2 (95% CI 1.3 to 13.1, p = 0.02). Oseltamivir-resistance was not statistically significantly associated with other clinical complications and symptoms.
  
  
  CONCLUSIONS
  Our results demonstrate that that a substantial number of patients may become oseltamivir-resistant as a result of oseltamivir use, and that oseltamivir resistance may be significantly associated with pneumonia. In contrast, zanamivir resistance has been rarely reported to date.
authors: Department of Clinical Epidemiology and Biostatistics, Faculty of Health Sciences, McMaster University, Hamilton, L8N 3Z5 Ontario, Canada. thorluk@mcmaster.ca
authors: Kristian
authors: K
authors: Thorlund
authors: Tahany
authors: T
authors: Awad
authors: Guy
authors: G
authors: Boivin
authors: Lehana
authors: L
authors: Thabane
references: Antivir Chem Chemother. 2010;21(2):71-84
references: 21107016
references: Pediatr Infect Dis J. 2001 Feb;20(2):127-33
references: 11224828
references: Commun Dis Intell Q Rep. 2008 Mar;32(1):57-62
references: 18522305
references: Virol J. 2010 May 08;7:88
references: 20459681
references: Euro Surveill. 2009 Nov 19;14(46):
references: 19941797
references: Pediatr Infect Dis J. 2010 Apr;29(4):384
references: 20351531
references: J Am Med Dir Assoc. 2005 Nov-Dec;6(6):359-66
references: 16286056
references: Clin Infect Dis. 2009 Feb 15;48(4):389-96
references: 19133796
references: Nature. 2005 Oct 20;437(7062):1108
references: 16228009
references: J Infect Dis. 1998 Nov;178(5):1257-62
references: 9780244
references: Med J Aust. 2010 Feb 1;192(3):166-8
references: 20121687
references: Antimicrob Agents Chemother. 2006 Jul;50(7):2395-402
references: 16801417
references: PLoS Pathog. 2010 Jul 22;6(7):e1001015
references: 20661429
references: Pediatr Infect Dis J. 2010 Apr;29(4):385-6
references: 20351533
references: N Engl J Med. 2000 Nov 2;343(18):1282-9
references: 11058672
references: Emerg Infect Dis. 2010 Jul;16(7):1185-6
references: 20587208
references: J Gen Virol. 2010 Apr;91(Pt 4):949-59
references: 20016036
references: N Engl J Med. 2010 Sep 30;363(14):1381-2
references: 20879894
references: Expert Opin Drug Saf. 2009 May;8(3):357-71
references: 19355841
references: Antimicrob Agents Chemother. 2002 Dec;46(12):3809-16
references: 12435681
references: MMWR Morb Mortal Wkly Rep. 2009 Aug 21;58(32):893-6
references: 19696719
references: Clin Infect Dis. 2006 Dec 15;43(12):1555-61
references: 17109288
references: Antivir Ther. 2005;10(8):901-10
references: 16430195
references: J Infect Dis. 2010 May 1;201(9):1397-403
references: 20350163
references: N Engl J Med. 2005 Dec 22;353(25):2667-72
references: 16371632
references: Expert Rev Anti Infect Ther. 2006 Oct;4(5):795-805
references: 17140356
references: N Engl J Med. 2009 Dec 3;361(23):2296-7
references: 19907034
references: Antiviral Res. 2010 Jul;87(1):16-21
references: 20385168
references: J Am Med Dir Assoc. 2005 Nov-Dec;6(6):367-74
references: 16286057
references: Antimicrob Agents Chemother. 2010 Mar;54(3):1256-64
references: 20047917
references: Influenza Other Respir Viruses. 2010 Jul;4(4):199-204
references: 20836794
references: Clin Infect Dis. 2010 Jun 1;50(11):1493-6
references: 20415572
references: Antivir Ther. 2000 Sep;5(3):205-13
references: 11075941
references: J Infect Dis. 2000 Apr;181(4):1471-4
references: 10762579
references: Antimicrob Agents Chemother. 2010 Nov;54(11):4568-74
references: 20713668
references: Euro Surveill. 2010 Apr 08;15(14):
references: 20394718
references: JAMA. 2007 Apr 4;297(13):1435-42
references: 17405969
references: Clin Infect Dis. 2010 Oct 15;51(8):983-4
references: 20858074
references: Antivir Ther. 2004 Aug;9(4):577-81
references: 15456089
references: N Engl J Med. 2010 Jan 7;362(1):88-9
references: 20032317
references: Pediatr Infect Dis J. 2000 May;19(5):410-7
references: 10819336
references: MMWR Morb Mortal Wkly Rep. 2009 Sep 11;58(35):969-72
references: 19745803
references: Euro Surveill. 2008 Jan 31;13(5):
references: 18445375
references: Emerg Infect Dis. 2009 Apr;15(4):552-60
references: 19331731
references: J Infect Dis. 2004 Feb 1;189(3):440-9
references: 14745701
references: JAMA. 2009 Mar 11;301(10):1034-41
references: 19255110
references: Emerg Infect Dis. 2009 Feb;15(2):155-62
references: 19193257
references: Stat Med. 2009 Feb 28;28(5):721-38
references: 19072749
references: J Clin Virol. 2010 Jul;48(3):220-2
references: 20447860
references: BMJ. 2008 Mar 15;336(7644):601-5
references: 18316340
references: Dtsch Arztebl Int. 2009 Nov;106(47):770-6
references: 20019861
references: J Infect. 2007 Sep;55(3):267-72
references: 17604839
references: Cochrane Database Syst Rev. 2010 Feb 17;(2):CD001265
references: 20166059
references: Emerg Infect Dis. 2010 Jul;16(7):1068-75
references: 20587176
references: Lancet. 2004 Aug 28-Sep 3;364(9436):759-65
references: 15337401
references: Antivir Ther. 2007;12(4 Pt B):603-16
references: 17944268
references: J Infect Dis. 2006 Mar 15;193(6):760-4
references: 16479508
references: J Infect Public Health. 2009;2(2):74-80
references: 20701864
references: Euro Surveill. 2010 Feb 11;15(6):
references: 20158979
references: Nature. 2008 Jun 26;453(7199):1258-61
references: 18480754